INTRODUCTION
============

Restless legs syndrome (RLS) is a neurological disorder characterized by an urge to move the legs, and is typically accompanied by unpleasant sensations in the legs.[@B1] Its symptoms are worse in the evening or at night, which leads to sleep disturbances such as sleep deprivation, insomnia, and sleep fragmentation.[@B2]

Neuroimaging and neurophysiological studies have demonstrated that extensive anatomical and functional abnormalities of the central nervous system are associated with RLS; for example, the gray-matter volume is increased in the thalamus[@B3] while it is decreased in the motor and somatosensory pathways.[@B4] Several neurophysiological studies have consistently demonstrated impairments of the central inhibition pathways in RLS patients.[@B5][@B6] Beta-band event-related synchronization is increased in the electroencephalograms (EEGs) of RLS patients, which indicates a substantial enhancement of motor cortical excitation.[@B7]

The pathophysiology of RLS has not been completely identified. However, dysfunction of the dopamine system is regarded as an important underlying cause because dopamine agonists can successfully improve various symptoms in RLS patients.[@B8] Transcranial magnetic stimulation (TMS) studies have demonstrated the reversal of impaired cortical inhibition following treatment with various dopamine agonists.[@B9][@B10]

RLS is a sleep disorder, and many RLS symptoms appear during sleep. Thus, to identify the mechanisms underlying the abnormalities during sleep and to estimate how these abnormalities may lead to cognitive and/or behavioral dysfunction, it is crucial to investigate the cortical activity of RLS patients during sleep. We are aware of only one previous electrophysiological study of RLS patients during sleep.[@B11] The EEG spectra during stage 2 sleep and rapid eye movement (REM) sleep did not differ significantly between RLS patients and healthy controls. High-frequency activities were increased temporally during arousals and periodic limb movements in both the patients and the controls. However, the increase in high-frequency activities was significantly dampened in the RLS patients.

Spectral analysis provides information regarding the synchronization of local neuronal populations. A functional connectivity analysis provides valuable additional insights regarding cooperation among distant neuronal populations. Interregional phase synchrony maps and graph-theory analyses have demonstrated that the human brain network has the properties of a so-called small-world network, whose structure is optimal for interregional information transfer.[@B12] The functional network during sleep also exhibits these characteristics, with local connectedness increasing from when awake to deep sleep stages.[@B13][@B14] This approach has been extended to clinical studies in order to identify functional abnormalities in patients. Several neurological and psychiatric diseases have been associated with the loss of small-world network characteristics.[@B15][@B16][@B17]

Based on whole-brain EEG recordings of drug-naïve RLS patients and healthy controls, we attempted to determine whether the functional network as well as the spectral power of neural activities during sleep differ significantly between RLS patients and healthy controls. We also investigated whether the functional abnormalities in RLS patients reversed following the administration of a dopamine agonist by analyzing EEGs from the same patients recorded 12 weeks after initiating dopaminergic treatment with pramipexole.

METHODS
=======

Subjects
--------

RLS was diagnosed by a neurologist (K.-Y.J.) based on the International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria utilizing the validated Korean version of the John Hopkins telephone diagnostic questionnaire in faceto- face interviews.[@B18] This questionnaire includes questions that help to exclude conditions that may mimic RLS.

A patient was included in the present study if he/she met the following criteria: 1) aged 18--70 years, 2) RLS symptom duration of longer than 1 year, 3) score on the International Restless Legs Syndrome Severity Scale (IRLS) of \>19, and 4) no prior treatment for RLS. The exclusion criteria were as follows: 1) presence of significant comorbidities likely to be associated with secondary RLS (e.g., pregnancy, chronic kidney disease, or peripheral neuropathy), 2) presence of RLS-mimicking disorders, 3) presence of sleep disorders other than RLS (e.g., sleep apnea, REM sleep behavior disorder, and parasomnia), as identified by polysomnography (PSG), and 4) presence of cognitive disorders that prevented the subject describing his/her symptoms.

Twelve drug-naïve RLS patients were enrolled in this study (11 females and 1 male), all of whom completed sleep-related questionnaires, which included the Epworth Sleepiness Scale,[@B19] the Insomnia Severity Index (ISI),[@B20] the Beck Depression Inventory-II (BDI-II),[@B21] and the Pittsburg Sleep Quality Index (PSQI).[@B22] The severity of RLS was assessed using the IRLS.[@B23]

A dopamine agonist, pramipexole, was administered to the patients every night at 1 hour prior to bedtime for a period of 12 weeks. The dosage of pramipexole at 1--2 weeks was 0.125 mg/day, and it was subsequently doubled at 2--4 weeks to 0.25 mg/day. At 5--12 weeks the dosage was increased based on the symptoms of the patient, with a maximum of 1 mg/day, and then maintained at that level. After the treatment, the same sleeprelated questionnaires and the IRLS were reassessed.

Age- and sex-matched volunteers served as a healthy control group (15 females and 1 male). All of the subjects in the control group completed the same sleep-related questionnaires. Subjects in the control group were excluded if they had a history of a sleep disorder (including RLS) and the long-term use of medications to treat a neurological disorder, a psychiatric disorder, or a chronic disease.

Written informed consent was obtained from each subject, and the experimental protocol was approved by the Local Ethics Committee (IRB number: ED11228).

Polysomnography
---------------

A single overnight PSG recording session was applied to all RLS patients before and after treatment; the first recording was made immediately prior to the administration of the first dose of pramipexole (i.e., the RLS baseline condition), and the second recording was made 12--16 weeks after commencing pramipexole administration (i.e., RLS follow-up condition). Only one overnight PSG recording session was applied to the subjects in the healthy control group. The recordings included a 19-channel EEG according to the international 10--20 system, a two-channel electrooculogram, submental and anterior tibialis electromyograms, and a surface electrocardiogram. A cannula was used to measure nasal air pressure, a thermistor was used to monitor the nasal and mouth airflow, piezoelectric bands were used to monitor thoracic and abdominal wall movements, and an oximeter was used to measure oxygen saturation; a snore sensor and body position sensors were also utilized. All signals were recorded at 200 samples/s.

The sleep stages were scored in 30-s epochs according to the scoring manual of the American Academy of Sleep Medicine.[@B24] Periodic leg movements during sleep (PLMS) were defined as a series of four consecutive leg movements that lasted 0.5--5 s separated by intervals of 5--90 s, in accordance with the criteria of the World Association of Sleep Medicine/IRLSSG.[@B25]

The reference electrode for the EEG recording was formed using linked ear electrodes, and the ground electrode was placed on the forehead. The impedances of all electrodes were lower than 5 kΩ. A bandpass filter (0.1--70 Hz) and a notch filter (60 Hz) were applied to reduce the background noise.

EEG preprocessing and spectral analysis
---------------------------------------

EEGs were re-referenced to the average reference. Considering the sleep stages, EEG analyses were performed in 30-s epochs segmented for sleep-stage scoring. A two-step procedure was applied to the raw EEG waveforms for artifact rejection. First, a high-pass filter with a cutoff frequency of 0.5 Hz was applied to reduce low-frequency artifacts, such as due to sweating and instrumentation drift. Epochs were excluded when the absolute amplitude exceeded 150 µV. The percentages of the remaining epochs after artifact rejection were 71.04±15.85% (mean±standard deviation) in the control group, 56.69±15.80% at the RLS baseline, and 69.58±12.97% in the RLS follow-up. The deterministic trends and direct current (DC) fluctuation were eliminated by removing the DC offset and detrending.[@B11] Furthermore, all waveforms were transformed into the current source density to mitigate the volume conduction problem.[@B26]

The power spectra of the 30-s epochs were estimated using Welch\'s method with the following parameters: 4-s windows, 800 samples, and Hamming window with a 50% overlap.[@B27] The resolution in the frequency domain was 0.25 Hz. The power spectra during each sleep stage were subsequently calculated by averaging the power spectra of all epochs associated with a specific stage. The spectral bands were defined as follows: delta (0.5--4 Hz), theta (4--8 Hz), alpha (8--12 Hz), and sigma (12--16 Hz).

Interregional phase synchrony and graph-theory analyses
-------------------------------------------------------

The interregional phase synchrony was quantified by calculating the phase coherence (PC).[@B28] Each 30-s epoch was initially transformed into narrowband signals covering the various frequency bands by bandpass filtering using a third-order zero-phase Butterworth filter. The instantaneous phase, 'θ(t)', was calculated from the narrowband signal and its Hilbert transform. The PC between two electrodes, 'i' and 'j', for the 'n^th^' epoch was calculated by averaging the phase difference over time points, 'T', as follows: $${PC}_{i,j,n} = \frac{1}{T}\left| {\sum\limits_{t = 1}^{T}{exp\left\{ {j\left\lbrack \theta_{i}\left\{ {t,n} \right\} - \theta_{j}\left\{ {t,n} \right\} \right\rbrack} \right\}}} \right|$$

The interregional phase synchrony for each sleep stage was obtained by averaging the PC values over all epochs within the stage.

The spatial pattern of the interregional phase synchrony may be treated as a graph that consists of nodes and edges, which allows the spatial pattern to be analyzed quantitatively using graph-theory measures.[@B29] The nodes of the graph correspond to the electrodes included in the phase synchrony analysis, and the edges correspond to the electrode pairs that exhibit significant phase synchrony. The graph can be represented by an adjacency matrix. Undirected binary element 'a~ij~' of the adjacency matrix represents a connection between nodes 'i' and 'j', and it is designated as 1 or 0 depending on the presence or absence of a significant connection between these nodes.

A set of numerical measures that describe the properties of the graph is calculated from the adjacency matrix. The clustering coefficient, 'C,' represents an index of local connectivity and is defined as follows:[@B29] $$C = \frac{1}{N}{\sum\limits_{i \in N}{C_{i} =}}\frac{1}{N}{\sum\limits_{i \in N}\frac{\sum_{j,h\in N}a_{ij}a_{ih}a_{jh}}{k_{i}\left( k_{i} - 1 \right)}}$$ where 'i', 'j', and h are the nodes of the graph. 'j' and 'h' are the nodes connected to node 'i' and are referred to as the neighboring nodes of node 'i'. 'k~i~' is called the degree of node 'i', which denotes the number of edges connected to that node. The value of 'C' varies from 0 to 1, and it is close to 1 when the neighboring nodes are highly interconnected. In the case of a high 'C' the network remains interconnected by neighboring nodes when a node is lost, and so 'C' represents a measure of the resilience of the network to errors.[@B12]

The characteristic path length, 'L', is defined as follows:[@B29] $$L = \frac{1}{N\left( N - 1 \right)}{\sum\limits_{i,j \in N,i \neq j}d_{i,j}}$$ where 'd~i,j~' is the minimum number of edges that must be traversed to go from node 'i' to node 'j'. 'L' corresponds to the average path length between all possible pairs of 'N' nodes, and so it provides a measure of the global connectedness, which quantifies the extent of graph integration and describes how easily and rapidly information can be transported in the network.

Brain functional and anatomical connectivity networks are empirical networks that have the characteristics of a smallworld network and so are appropriate for interregional information transfer.[@B30] The small-worldness index (SWI) is defined as the ratio between the normalized clustering coefficient and the characteristic path length, as follows:[@B31] $$SWI = \frac{C_{\text{norm}}}{L_{\text{norm}}} = \frac{{C/C}_{\text{rand}}}{{L/L}_{\text{rand}}}$$ where 'C~norm~' and 'L~norm~' comprise the normalized clustering coefficient and the characteristic path length, respectively, which are normalized by the values of a random network. The graph-theory indices of a random network can be obtained by creating, say, 50 random networks with the same degree 'K' of the network being assessed. The mean values of the clustering coefficients and characteristic path lengths of these 50 random networks would then subsequently be used: 'C~rand~' and 'L~rand~', respectively. For a typical small-world network, 'C~norm~' is greater than 1 while 'L~norm~' is close to 1. The topological properties of two dissimilar networks can be compared by adjusting the degrees of their two graphs to be identical in order to eliminate the effect of the number of connections.[@B17][@B32]

Statistical comparison
----------------------

The sample was small in this study, and so we applied Kolmogorov-Smirnov tests to check that the variables conformed to a normal distribution. Some of them did not pass these tests, and so we used nonparametric tests for further statistical analyses. The RLS patients before receiving dopamine agonist treatment (i.e., the RLS baseline) and the healthy controls were compared using Mann-Whitney U-tests. Wilcoxon signed-rank tests were used to compare patients between before and after treatment; that is, between the RLS baseline and the RLS follow-up. The Kruskal-Wallis test was used to compare the SWI among the sleep stages in each group. Post-hoc tests were performed using the Wilcoxon signed-rank test, and multiple comparisons were corrected using the Bonferroni method.

RESULTS
=======

Clinical and sleep-related variables
------------------------------------

The demographic data and clinical characteristics of the participants are presented in [Table 1](#T1){ref-type="table"}. The BDI-II scores for the RLS patients prior to dopaminergic treatment (RLS baseline) were within the range corresponding to mild depression and were also significantly elevated compared to those of the healthy controls (*p*=0.017 by Mann-Whitney U-test). The sleep quality was worse for the RLS baseline than for the healthy controls, as indicated by the ISI and PSQI score being significantly higher for the RLS baseline (both *p*\<0.001 in Mann-Whitney Utests).

The IRLS score for the RLS baseline was within the range corresponding to severe RLS, and it decreased significantly after pramipexole treatment (the RLS follow-up) to a moderate level (*p*=0.028 in a Wilcoxon signed-ranked test). The sleep quality was also slightly improved following treatment. A significant difference between before and after the treatment was found only for the ISI (*p*=0.019 in a Wilcoxon signed-rank test). The scores on the sleep-related questionnaires remained worse than those for the healthy controls even after the RLS patients had received treatment (*p*\<0.001 for both the ISI and PSQI in Mann-Whitney U-tests).

PSG findings
------------

[Table 2](#T2){ref-type="table"} summarizes the PSG findings. In general, compared to healthy controls, the RLS patients exhibited abnormally poor sleep-related variables. For example, the REM latency and the sleep efficiency tended to be increased and decreased, respectively, at the RLS baseline, although the differences were not significant. The PLMS index was significantly higher for the RLS baseline than the healthy controls (*p*=0.004 in a Mann-Whitney U-test).

After administering dopaminergic treatment to the RLS patients, the REM latency and the PLMS index were significantly reduced and the sleep efficiency was significantly increased (*p*=0.015, 0.006, and 0.019 in Wilcoxon signed-rank tests).

Spectral characteristics of EEGs
--------------------------------

[Fig. 1A](#F1){ref-type="fig"} shows the spectral powers of the EEG averaged over the F3, Fz, F4, C3, Cz, C4, P3, Pz, and P4 electrodes during all sleep stages. All values of the spectral power in each frequency band as well as the results of the statistical comparisons are presented in [Table 3](#T3){ref-type="table"}. The spectral power was higher for the RLS patients in the baseline condition than for the healthy controls in all frequency bands, but the difference was significant only for the delta band (*p*=0.017). Dopaminergic treatment resulted in significant reductions in spectral power in all frequency bands, with the decrease being larger in the delta band than in the theta, alpha, and sigma bands (*p*=0.002, 0.005, 0.002, and 0.003, respectively). Remarkably, the spectral powers in all frequency bands no longer differed significantly between the RLS patients and the healthy controls following dopaminergic treatment.

The correlation between the delta-band power and the IRLS score was investigated for the RLS patients ([Fig. 1B](#F1){ref-type="fig"}). The deltaband power was significantly correlated with the IRLS score in the RLS patients in the baseline condition (r=0.606 and *p*=0.037 in Spearman\'s rank correlation).

To summarize the EEG spectral characteristics, abnormal cortical activities associated with RLS were most apparent in the delta band. Thus, further analyses using functional connectivity and graph theory were applied to the delta-band activity.

Interregional phase synchrony and graph-theory analyses
-------------------------------------------------------

[Fig. 2](#F2){ref-type="fig"} presents the SWI as a function of the degree of the network (i.e., 'K') in each sleep stage. The SWI differed significantly between the groups only for sleep stage N3 ([Fig. 2A](#F2){ref-type="fig"}): it was significantly lower for the RLS baseline than for the healthy controls when 'K' was between 6.3 and 6.5 (*p*\<0.047 in a Mann-Whitney U-test). The SWI increased significantly after dopaminergic treatment in stage N3 for 'K' values between 3.5 and 5.8 (*p*\<0.041 in a Wilcoxon signed-rank test) ([Fig. 2B](#F2){ref-type="fig"}). The optimal values of 'K' were defined as 3.5--6.5 based on where there were significant differences in [Fig. 2](#F2){ref-type="fig"}.

[Fig. 3](#F3){ref-type="fig"} presents the SWI, 'C~norm~', and 'L~norm~' averaged across the optimal values of K. The SWI differed significantly with sleep stage only in the healthy controls and at the RLS follow-up (*p*=0.011 and 0.005, respectively, in Kruskal-Wallis tests, and with *p*=0.915 for the RLS baseline) ([Fig. 3A](#F3){ref-type="fig"}, [Table 4](#T4){ref-type="table"}). The SWI was higher during deeper sleep stages in both the healthy controls and at the RLS follow-up, and was highest in stage N3. In the healthy controls, the SWI was significantly higher in stages N2 and N3 than when awake (*p*=0.009 and 0.011, respectively, in Wilcoxon signed-rank tests with Bonferroni correction). In the RLS follow-up, the SWI was significantly higher in stage N3 than when awake (*p*=0.029 in a Wilcoxon signed-rank test with Bonferroni correction), and in stage N2 than during REM sleep (*p*=0.047 in a Wilcoxon signed-rank test with Bonferroni correction).

The characteristics of the changes in 'C~norm~' across sleep stages were largely identical to those in the SWI ([Fig. 3B](#F3){ref-type="fig"}). 'C~norm~' differed significantly with sleep stage only in the healthy controls and RLS follow-up (*p*=0.006 and 0.004, respectively, in Kruskal-Wallis tests, and with *p*=0.937 for the RLS baseline) ([Table 4](#T4){ref-type="table"}). 'C~norm~' was higher in the deeper sleep stage in both the healthy controls and RLS follow-up, and peaked in stage N3. 'C~norm~' was higher in stages N2 and N3 than when awake in the healthy controls (*p*=0.006 and 0.004, respectively, in Wilcoxon signed-rank tests with Bonferroni correction). In the RLS-follow-up, 'C~norm~' was significantly higher in stages N2 and N3 than when awake (*p*=0.047 and 0.022, respectively, in Wilcoxon signed-rank tests with Bonferroni correction) and than during REM sleep and stage N1 (both *p*=0.047 in Wilcoxon signed-rank tests with Bonferroni correction).

'L~norm~' did not differ significantly with sleep stage in any of the groups (*p*=0.239, 0.828, and 0.070 for the controls, RLS baseline, and RLS follow-up, respectively, in Kruskal-Wallis tests). The values of the graph-theory measures and the results of the statistical comparisons are presented in [Table 4](#T4){ref-type="table"}.

DISCUSSION
==========

The aims of this study were to characterize abnormal cortical activity during sleep in RLS patients and to identify the effects of treatment with a dopamine agonist. We found significant increases in the delta-band power and disruption of the small-world network in RLS patients compared to healthy controls. Moreover, these abnormalities were successfully treated with a dopamine agonist.

Increased delta-band power during sleep
---------------------------------------

Several electrophysiological studies have demonstrated cortical hyperexcitability associated with RLS when these patients are awake.[@B7][@B33][@B34] Malfunction of the motor inhibition circuitry in RLS patients was revealed by paired-pulse TMS.[@B33][@B34] Movement-related beta-band synchronization was found to be notably higher in RLS patients than in healthy controls.[@B7]

The delta rhythm in sleep EEG, especially during the deep non-REM sleep stage, has been regarded as an important indicator of the homeostatic down-regulation process and sleep deficiency.[@B35] According to the synaptic homeostatic hypothesis,[@B35] synaptic potentiation is strengthened during the daytime but reduced to baseline levels during sleep. Such synaptic downscaling has been demonstrated to induce the delta rhythm during sleep, and with the proportion of this rhythm being proportional to the degree of synaptic potentiation when awake.[@B36] This finding is supported by several studies identifying an increased delta rhythm in response to enhanced synaptic potentiation when awake, which was found to be caused by learning, TMS, or sleep deprivation.[@B37][@B38][@B39] An abnormally high delta rhythm may therefore reflect an increased demand for homeostatic regulation due to cortical hyperexcitability during wakefulness associated with RLS. This phenomenon may also be supported by the strong and significant correlation between the delta-band power and the IRLS score, which was observed only for the RLS patients in the baseline condition.

Only one previous study reported in the literature has investigated the sleep EEGs of RLS patients, and found that they were significantly altered only during arousal or PLMS-associated arousal, especially for high-frequency activity, with the findings not differing in healthy controls.[@B11] Additional studies may be required to determine the reason for this discrepancy. However, several methodological differences should be considered; for example, Hornyak et al.[@B11] investigated non-REM stage 2 sleep and REM sleep at two electrodes (C3-A1 and C4-A2), and defined the delta band as 0.1-3.5 Hz, while in the present study we investigated all sleep stages at broader scalp sites, and the delta band was defined as ranging from 0.5 to 4 Hz.

Loss of small-world network property during deep sleep
------------------------------------------------------

We observed disruption of the small-world network in RLS patients during deep sleep (stage N3). This disruption was due to reduced local clustering (i.e., lower clustering coefficient), although the path length was not altered significantly. Since the human brain exhibits the properties of a small-world network, which is characterized by a high local connectedness and an effective global connectedness, it can be considered an optimal structure for interregional information transfer.[@B40] The functional brain network during sleep has also been characterized as a small-world network, with abundant local clustering in the deep-sleep stages.[@B13][@B14] The higher local connectedness during deep sleep may be related to the previously described enhanced homeostatic downscaling during deep sleep, considering that the downscaling occurs locally.[@B41] This perspective is supported by converging evidence that the sleep delta rhythm is locally modulated under enhanced synaptic potentiation.[@B38][@B39][@B42] Homeostatic down-regulation in sleep has been considered to play a crucial role in learning and memory.[@B35] In addition to abnormal hyperactivity in the delta band, the weak local clustering and the resulting homeostatic down-regulation may be related to disrupted cognitive functions--such as frontal executive function, attention, and working memory--that have been reported in RLS patients.[@B43][@B44][@B45][@B46]

In contrast to the situation in the healthy controls, the SWI of the RLS patients did not differ significantly with the sleep stage, and it was significantly lower than that in the healthy controls during deep sleep. All graph-theory measures in this study were normalized by random surrogate data, and so the decrease in the SWI close to 1 in RLS may indicate that the functional brain network becomes close to a random network. We have previously demonstrated a disruption in the functional brain network in RLS when performing a cognitive task;[@B47] the current study extends this by indicating that some of the deficits found when RLS patients are awake may also be observed during sleep.

A disrupted functional brain network has been demonstrated in other neurological/psychiatric diseases accompanied by cognitive deficits.[@B15][@B16][@B17] A 'randomization process' in the functional brain network has been reported in various functional states--such as when performing cognitive tasks, in the awake-but-resting state, and during sleep--in several diseases, including schizophrenia, Alzheimer\'s disease, and depression. This randomization process has been suggested as a general pattern of neuropsychiatric diseases.[@B15]

Dysfunction of the dopamine system and effects of dopaminergic medication
-------------------------------------------------------------------------

Previous studies have investigated the efficacy of dopamine agonists in improving the sensory and motor symptoms,[@B48][@B49] sleep disturbances,[@B50] and mental illnesses[@B51][@B52] associated with RLS. Dysregulation of the dopamine system has been considered a crucial mechanism underlying RLS pathophysiology. The present study has demonstrated that treatment with a dopamine agonist is effective at improving the abnormal neural activity and functional brain network in RLS, in addition to improving the IRLS score and the scores in several sleep-related questionnaires.

Previous studies have consistently demonstrated that cortical hyperexcitability in RLS responds well to dopaminergic treatments.[@B9][@B10][@B53] Based on these findings, our results suggest that the reversal of cortical hyperexcitability in RLS leads to a reduced need for homeostatic down-regulation during sleep. However, it remains to be clarified whether the altered cortical activity in RLS comprises an intrinsic characteristic of dopaminergic dysfunction or a secondary symptom caused by sleep disturbances. Considering that the necessity for homeostatic down-regulation of cortical activity was reduced to a normal level during sleep deprivation,[@B54] we believe that excessive delta rhythms that are characteristic of RLS patients do not result from sleep disturbances.

Dopaminergic agonist treatment reversed the impaired small-worldness of the functional brain network during deep sleep in RLS patients. Previous studies have demonstrated alterations in the brain network in other diseases caused by dopaminergic dysfunction, such as Parkinson\'s disease.[@B55][@B56][@B57][@B58] Our findings therefore suggest that the functional network characteristics identified in the RLS patients are associated with an impaired dopamine system and that they were reversed by pramipexole treatment. This result is also consistent with a previous finding that dopamine antagonist administration impairs both local and global connectedness of the brain network.[@B59]

Limitations of this study
-------------------------

This study was subject to several limitations. First, our results were obtained from a small number of patients, all of whom had severe RLS. Further studies that include more patients with broader severity ranges would be helpful for generalizing the findings of this study. Second, the network analysis was based on scalp EEGs recorded using a small number of channels. Further studies using larger numbers of EEG channels along with cortical source imaging would help to explain the cortical network characteristics of RLS patients in more detail.

Conclusion
----------

Abnormal spectral and functional network characteristics of neural activities were observed in RLS patients during sleep, and these abnormalities were successfully reversed by dopamine agonist treatment. These findings suggest that an impaired dopamine system is an important underlying cause of RLS. We consider that our findings represent valuable information for identifying the mechanisms underlying cortical dysfunction in RLS patients.
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![Spectral powers in electroencephalograms (EEGs). A: Comparison of spectral powers in EEGs among groups. The spectral power was obtained by averaging the log-transformed power for every sleep stage (awake, N1, N2, N3, and REM) and nine electrodes (F3, Fz, F4, C3, Cz, C4, P3, Pz, and P4). The error bars indicate standard errors (^\*^*p*\<0.05, ^†^*p*\<0.01, and ^‡^*p*\<0.001, respectively, in Mann-Whitney U-tests and Wilcoxon signed-rank tests). B: Correlation between delta-band power and IRLS scores in RLS patients (baseline condition). Delta-band power was obtained by averaging the log-transformed power for the nine electrodes and all sleep stages. Spearman\'s rank correlation coefficient (r) was 0.606 (*p*=0.037). IRLS: International Restless Legs Syndrome Severity Scale, REM: rapid eye movement, RLS: restless legs syndrome.](jcn-13-340-g001){#F1}

![SWI as a function of degree K in each sleep stage. A: Comparison between the control (black dashed lines) and RLS baseline (denoted by red solid lines). B: Comparison between the RLS baseline (denoted by red lines) and RLS follow-up (denoted by blue lines). The SWI was plotted as the number of identical connections for the three groups. Shading indicates standard errors. Black downward triangles indicate *p*\<0.05 in Mann-Whitney U-tests and Wilcoxon signed-rank tests for (A) and (B), respectively. REM: rapid eye movement, RLS: restless legs syndrome, SWI: smallworldness index.](jcn-13-340-g002){#F2}

![Graph-theory measures for each sleep stage in each group. Normalized clustering coefficient (A), normalized characteristic path length (B), and SWI (C). Each graph-theory measure was obtained by averaging the values from K=3.5 to K=6.5. Error bars indicate standard errors (^\*^*p*\<0.05 and ^†^*p*\<0.01, respectively, in Wilcoxon signed-rank tests with Bonferroni correction). REM: rapid eye movement, RLS: restless legs syndrome.](jcn-13-340-g003){#F3}

###### Clinical characteristics and scores on the sleep-related questionnaires

![](jcn-13-340-i001)

                                 Control (A)   RLS baseline (B)   RLS follow-up (C)   *p*               
  ------------------------------ ------------- ------------------ ------------------- --------- ------- ---------
  Clinical characteristic                                                                               
   *n*                           16            12                                     \-        \-      
   Age (years)                   48.38±9.04    47.92±9.41         48.00±9.28          0.982     0.906   0.945
   Sex, F/M                      15/1          11/1               \-                  \-        \-      
   IRLS score                    \-            29.92±4.98         13.50±10.94         \-        0.028   \-
   BDI-II                        7.44±5.33     15.42±9.11         8.92±5.87           0.017     0.084   0.568
  Treatment with pramipexole                                                                            
   Period (weeks)                \-            12                 \-                  \-        \-      
   Dosage (mg/day)               \-            0.28±0.32          \-                  \-        \-      
  Sleep-related questionnaires                                                                          
   ISI                           2.88±1.93     17.75±6.66         10.33±5.69          \<0.001   0.019   \<0.001
   PSQI                          4.25±1.77     13.58±6.46         10.08±4.06          \<0.001   0.168   \<0.001

Data are mean±standard deviation values.

^\*^Control vs. RLS baseline in Mann-Whitney U-tests, ^†^RLS baseline vs. RLS follow-up in Wilcoxon signed-rank tests, ^‡^Control vs. RLS follow-up in Mann-Whitney U-tests.

BDI-II: Beck Depression Inventory-II, F: female, IRLS: International Restless Legs Syndrome Severity Scale, ISI: Insomnia Severity Index, M: male, PSQI: Pittsburgh Sleep Quality Index, RLS: restless legs syndrome.

###### Polysomnography findings

![](jcn-13-340-i002)

  Parameter                Control (A) (*n*=16)   RLS baseline (B) (*n*=12)   RLS follow-up (C) (*n*=12)   *p*             
  ------------------------ ---------------------- --------------------------- ---------------------------- ------- ------- -------
  Total sleep time (min)   394.94±51.65           334.88±91.03                396.16±42.05                 0.100   0.099   0.909
  Sleep latency (min)      7.41±4.86              20.29±30.95                 7.38±5.00                    0.371   0.091   0.945
  REM latency (min)        96.97±40.08            117.25±42.95                79.00±32.94                  0.090   0.015   0.241
  WASO (min)               45.84±31.56            70.10±49.45                 47.80±29.42                  0.110   0.117   0.802
  Sleep efficiency (%)     87.98±7.28             77.78±17.97                 87.76±7.73                   0.082   0.019   0.837
  Stage N1 (%)             18.03±9.54             20.57±9.59                  16.82±6.78                   0.324   0.182   0.945
  Stage N2 (%)             43.89±7.48             39.30±12.25                 37.93±12.77                  0.347   0.556   0.302
  Stage N3 (%)             15.39±7.54             17.99±15.07                 21.30±13.41                  0.945   0.480   0.280
  Stage REM (%)            22.70±4.90             22.14±6.54                  23.95±7.35                   0.599   0.530   0.537
  Apnea/hypopnea index     2.21±3.45              3.32±4.41                   2.61±3.53                    0.280   0.695   0.423
  Arousal index            18.08±9.24             20.68±9.20                  16.20±6.72                   0.174   0.182   0.732
  PLMS index               3.08±4.07              23.80±26.00                 5.29±4.12                    0.004   0.006   0.121
  PLMS arousal index       1.77±2.37              6.53±9.24                   2.34±2.50                    0.133   0.169   0.478

Data are mean±standard deviation values.

^\*^Control vs. RLS baseline in Mann-Whitney U-tests, ^†^RLS baseline vs. RLS follow-up in Wilcoxon signed-rank tests, ^‡^Control vs. RLS follow-up in Mann-Whitney U-tests.

PLMS: periodic leg movements during sleep, REM: rapid eye movement, RLS: restless legs syndrome, WASO: wakefulness after sleep onset.

###### Statistical comparison of spectral powers

![](jcn-13-340-i003)

  Band    Control (A)   RLS baseline (B)   RLS follow-up (C)   *p*             
  ------- ------------- ------------------ ------------------- ------- ------- -------
  Delta   41.36±1.81    44.28±3.73         41.27±1.86          0.017   0.002   0.948
  Theta   34.08±2.26    37.45±4.52         34.16±3.03          0.059   0.005   0.983
  Alpha   32.40±2.92    35.07±4.50         31.92±3.30          0.100   0.002   0.746
  Sigma   29.54±2.50    31.57±3.60         28.81±2.53          0.121   0.003   0.589

Data are mean±standard deviation values in dB.

^\*^Control vs. RLS baseline in Mann-Whitney U-tests, ^†^RLS baseline vs. RLS follow-up in Wilcoxon signed-rank tests, ^‡^Control vs. RLS follow-up in Mann-Whitney U-tests.

RLS: restless legs syndrome.

###### Graph-theory measures and summary of statistical comparisons among sleep stages within each group

![](jcn-13-340-i004)

                                          Awake       N1          N2          N3          REM         *p*     Post hoc
  --------------------------------------- ----------- ----------- ----------- ----------- ----------- ------- ---------------------------------------------------------------
  Small-worldness index                                                                                       
   Control                                1.14±0.16   1.21±0.15   1.29±0.19   1.37±0.22   1.19±0.16   0.011   \[N2\>W\]^†^, \[N3\>W\]^\*^
   RLS baseline                           1.20±0.17   1.21±0.19   1.24±0.25   1.26±0.22   1.22±0.17   0.915   
   RLS follow-up                          1.15±0.24   1.25±0.20   1.41±0.21   1.45±0.18   1.23±0.19   0.005   \[N3\>W\]^\*^, \[N2\>REM\]^\*^
  Normalized clustering coefficient                                                                           
   Control                                1.18±0.18   1.25±0.17   1.34±0.22   1.44±0.24   1.23±0.17   0.006   \[N2\>W\]^†^, \[N3\>W\]^†^
   RLS baseline                           1.25±0.18   1.24±0.21   1.31±0.29   1.32±0.26   1.27±0.17   0.937   
   RLS follow-up                          1.18±0.24   1.27±0.23   1.47±0.23   1.53±0.22   1.27±0.20   0.004   \[N2\>W\]^\*^, \[N3\>W\]^\*^, \[N3\>N1\]^\*^, \[N2\>REM\]^\*^
  Normalized characteristic path length                                                                       
   Control                                1.03±0.03   1.03±0.02   1.04±0.02   1.05±0.03   1.03±0.02   0.239   
   RLS baseline                           1.04±0.03   1.03±0.02   1.05±0.04   1.04±0.04   1.05±0.03   0.828   
   RLS follow-up                          1.03±0.05   1.02±0.02   1.04±0.03   1.05±0.03   1.03±0.02   0.070   

Data are mean±standard deviation values.

^\*^*p*\<0.05 and ^†^*p*\<0.01, respectively, in Wilcoxon signed-rank tests with Bonferroni correction.

REM: rapid eye movement, RLS: restless legs syndrome, W: awake.

[^1]: ^\*^These authors have contributed equally to this work.
